ROBOT Report - vo

VO:0000018

A Brucella abortus vaccine that expresses Cu/Zn SOD with DNA plasmid pcDNA.

1

WARN

VO:0000035

a vaccinia virus vaccine that is a freeze-dried calf lymph smallpox vaccine, specifically, Dryvax is a live-virus preparation of vaccinia prepared from calf lymph.

2

WARN

VO:0000069

A Measles-Mumps-Rubella vaccine that is live attenuated and manufactured by Merck & Co, Inc.

3

WARN

VO:0000070

A Measles-Mumps vaccine that is manufactured by Merck and used for human.

4

WARN

VO:0000079

an influenza vaccine that is similar to Fluzone but has high dose.

5

WARN

VO:0000091

A Measles-Mumps-Rubella-Vericella vaccine that is live and manufactured by Merck & Co, Inc.

6

WARN

VO:0000137

A vaccine role that indicates the vaccine being a combination vaccine.

7

WARN

VO:0000145

a vaccine component role that inheres in a recombit vaccine vector as a vaccine component. The combination of a recombit vaccine vector and a heterogenous protective antigen(s) inserted inside the vector for a recombit vector vaccine.

8

WARN

VO:0000147

an adjuvant role that inheres in a vaccine component which is added as part of a vaccine and induces enhanced adaptive immune response to the vaccine antigen.

9

WARN

VO:0000154

A Brucella abortus gene that has the name sodC and comes from strain 2308.

10

WARN

VO:0000166

a vaccine vector that uses a live bacterium as the vector

11

WARN

VO:0000194

a USA licensed vaccine role that inheres ina vaccine approven to be by the US FDA to be used for humans in the USA.

12

WARN

VO:0000207

A vaccine contraindication is a contraindication that increases the risks of a vaccination.

13

WARN

VO:0000208

A vaccine role that is not licensed or in clinical trial; instead, it has been experimently approved to induce protection or treatment effect in vivo in at least an experimental animal model.

14

WARN

VO:0000211

an organismal quality of a whole organism vaccine where the whole organism is inactivated/killed and lacks the capability of replication.

15

WARN

VO:0000310

a vaccine additive that stabilizes the vaccine emulsification manufacturing process and makes emulsion of the vaccine easier.

16

WARN

VO:0000335

A vaccination site that is used for injection of a vaccine.

17

WARN

VO:0000369

A 'has vaccine component' relation that specifies the plasmid used for development of a particular DNA vaccine.

18

WARN

VO:0000375

IAO:0000112

'Mycobacterium avium relA mutant vaccine' includes a gene mutation of relA from virulent Mycobacterium avium.

19

WARN

VO:0000384

PMID:18472194

20

WARN

VO:0000400

A vaccine that contains one vaccine for priming and at least one other vaccine for boosting.

21

WARN

VO:0000401

A prime-boost vaccine that contains one DNA vaccine for priming and at least one other vaccine for boosting.

22

WARN

VO:0000435

a vaccine component that is composed of a plasmid and used in the generation of a DNA vaccine.

23

WARN

VO:0000441

Role of a material entity in an investigation, which has not been experimentally or clinically verified to induce a protection or treatment in vivo in a recipient organism.

24

WARN

VO:0000465

a S. aureus vaccine that uses bacterin as the protective antigen.

25

WARN

VO:0000467

a S. aureus vaccine that uses the bacterial phage lysate as the protective antigen.

26

WARN

VO:0000469

a bacterial vaccine that uses bacterin from a bacterial strain isolated from a herd with a purpose to generate hard-specific vaccine.

27

WARN

VO:0000470

an autogenous bacterin vaccine that is prepared for poultry use.

28

WARN

VO:0000476

A 'has vaccine component' relation that specifies a gene inserted to DNA vaccine plasmid for development of a particular DNA vaccine, and this gene encodes for a protein antigen.

29

WARN

VO:0000483

A subunit vaccine that is made using a part of whole organism as subunit for vaccine development.

30

WARN

VO:0000504

a vaccine role that indicates the vaccine being a whole organism vaccine.

31

WARN

VO:0000512

a viral vaccine against a disease caused by a virus belong to Poxviridae.

32

WARN

VO:0000524

IAO:0000116

This relation only works for those vaccine antigen that is physically part of a vaccine preparation. It does not include those antigens that are not part of vaccine. For example, a protein antigen expressed in a DNA vaccine is not a part of vaccine pe ser. In this case, the vaccine expresses the protein, but the gene is part of the vaccine, not the protein. For the case, we can use the relation 'DNA vaccine expresses protein antigen' under the relation 'expresses'.

33

WARN

VO:0000532

A route of administration that is loacted in the hypodermis (subcutaneous tissue) region.

34

WARN

VO:0000560

A toxin is a poisonous substance produced within living cells or organisms; man-made substances created by artificial processes are thus excluded.

35

WARN

VO:0000574

A path that is located in gross anatomical part of an organism (e.g., human) and is used for administering a vaccine, a drug, fluid, poison, or other substance into the body.

36

WARN

VO:0000577

A subunit vaccine that uses small peptide(s) as immunoepitopes.

37

WARN

VO:0000599

IAO:0000116

a vaccine component that uses a microbe (e.g., bacterium, virus, and parasitic organism) as a vector that is inserted with the DNA(s) of a heterologous protective antigen(s) to generate a \"recombit vector vaccine\". The microorganism used as a vector generally has a stable non or low pathogenic phenotype for the species the vaccine is intended for.

38

WARN

VO:0000608

An 'expresses' relation that specifies a relation between a DNA vaccine and a protein antigen to be expressed by the DNA vaccine.

39

WARN

VO:0000615

Role that inheres in a prepared material entity that is designed to induce protection or treatment for a disease or infection.

40

WARN

VO:0000617

A role that inheres in a material entity that becomes an ingredient of a vaccine.

41

WARN

VO:0000622

a vaccine antigen role that inheres in a vaccine antigen which is capable of inducing protective immunity.

42

WARN

VO:0000623

A vaccine role that indicates the vaccine being a DNA vaccine.

43

WARN

VO:0000624

A vaccine role that indicates the vaccine being a subunit vaccine.

44

WARN

VO:0000625

A vaccine role that indicates the vaccine being a conjugate vaccine.

45

WARN

VO:0000636

A vaccine role that indicates the vaccine being a recombit vector vaccine.

46

WARN

VO:0000671

A Salmonella vaccine against typhoid fever (or called typoid), caused by Salmonella enterica enterica, serovar Typhi.

47

WARN

VO:0000675

a Streptococcal vaccine that is used against S. pneumoniae infection, which causes pneumococcal diseases.

48

WARN

VO:0000685

a recombit vector vaccine role that inheres in a bacterium that carries a vaccine antigen for development of a particular vaccine

49

WARN

VO:0000692

A subunit vaccine role that indicates the vaccine being a peptide vaccine.

50

WARN

VO:0000702

a recombit vector vaccine role that inheres in a virus that carries a vaccine antigen for development of a particular vaccine

51

WARN

VO:0000728

A vaccine role that indicates the vaccine being a RNA vaccine.

52

WARN

VO:0000767

A bacterial vaccine that protects against diseases caused by various species of Rickettsia. Typhus is any of several similar diseases caused by Rickettsia bacteria. So Rickettsial vaccine is also called typhus vaccine.

53

WARN

VO:0000794

A Brucella abortus gene that has the name wboA and comes from strain 2308.

54

WARN

VO:0000799

An object property that represents a mutational relation between a vaccine organism and another material (e.g., gene or protein). the mutated material initially exists in the original wildtype organism.

55

WARN

VO:0000807

A vaccine role that indicates the vaccine being a toxoid vaccine.

56

WARN

VO:0000818

An object property that specifies a relation between a vaccine and a vaccine virmugen.

57

WARN

VO:0000857

Process profile that is measurable and the measured data indicates the degree of immunological protection in the vaccine recipient. More specifically, it is the process in some immune response component (such as gene, protein, etc.) which serves as an immune biomarker.

58

WARN

VO:0000922

a vaccine stablizer that is based on monosodium glutamate.

59

WARN

VO:0000931

a cell culture residual in vaccine that is residual protein from cell culture.

60

WARN

VO:0000957

a B. abortus vaccine that uses a recombit vector.

61

WARN

VO:0001014

a live attenuated quality of a bacterial vaccine strain.

62

WARN

VO:0001015

a live attenuated quality of a virus vaccine strain.

63

WARN

VO:0001019

an avian reovirus vaccine that using live attenauted reovirus.

64

WARN

VO:0001021

a feline panleukopenia virus vaccine where the virus used is live attenuated.

65

WARN

VO:0001028

a parasite vaccine vector using a live attenuated Leishmania tarentolae strain.

66

WARN

VO:0001050

IAO:0000118

PrV vaccine vector

67

WARN

VO:0001060

IAO:0000118

NDV vaccine vector

68

WARN

VO:0001084

a viral vaccine vector that uses a baculovirus as the vector

69

WARN

VO:0001107

a vaccinia virus vector that uses the Modified Vaccinia Ankara (MVA) virus.

70

WARN

VO:0001109

a vaccinia virus vector that uses the MVTT vaccine strain as the vector. MVTT is an attenuated vaccine strain.

71

WARN

VO:0001111

A poxvirus vaccine vector that uses an attenuated lumpy skin disease virus as the vector.

72

WARN

VO:0001128

a canarypox vaccine vector that uses an attenuated canarypox virus strain ALVAC. The ALVAC vector is a canarypox virus clone obtained after four rounds of plaque purification of a strain from a vaccine for canaries.

73

WARN

VO:0001186

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

74

WARN

VO:0001188

A measurement datum that represents a vaccine strain. Different strains can be represented using distinct digital numbers.

75

WARN

VO:0001188

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

76

WARN

VO:0001189

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

77

WARN

VO:0001190

A measurement datum that indicates the usage of a vaccine adjuvant. Different digital numbers can be used to represent different adjuvants.

78

WARN

VO:0001190

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

79

WARN

VO:0001191

A measurement datum that represents a specific protective antigen used in a vaccine. The antigen can be represented by a described digit.

80

WARN

VO:0001191

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

81

WARN

VO:0001192

A measurement datum that represents a specific mutated gene from a vaccine strain. The mutated can be represented by a described digit.

82

WARN

VO:0001192

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

83

WARN

VO:0001193

A measurement datum that represents a specific mouse strain used for vaccination. Different strains can be represented using discretized digitals. For example, 0 = BALB/c; 1 = CD1; 2 = mixed/outbred; 3 = C57BL/6; 4 = OF1; 5 = 129/Sv; 6 = Swiss albino.

84

WARN

VO:0001193

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

85

WARN

VO:0001194

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

86

WARN

VO:0001195

A measurement datum that represents a specific route (e.g., i.p.) used for vaccination. Different routes can be represented using discretized digitals. 0 = IP; 1 = PO; 2 = SC; 3 = IM; 4 = IN; 6 = IG; 7 = IV; 8 = ID.

87

WARN

VO:0001195

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

88

WARN

VO:0001196

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

89

WARN

VO:0001197

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

90

WARN

VO:0001198

A measurement datum that represents a specific pathogen strain used for animal challenge study. Different pathogen strains can be represented using discretized digitals.

91

WARN

VO:0001198

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

92

WARN

VO:0001199

A measurement datum that represents a specific pathogen used for animal challenge study. Different pathogens can be represented using discretized digitals.

93

WARN

VO:0001199

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

94

WARN

VO:0001202

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

95

WARN

VO:0001203

A measurement datum that represents a length of days as the interval between a vaccination and a challenge in a specific vaccine protection study.

96

WARN

VO:0001203

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

97

WARN

VO:0001204

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

98

WARN

VO:0001205

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

99

WARN

VO:0001206

Todd TE, Tibi O, Lin Y, Sayers S, Bronner DN, Xiang Z, He Y. Meta-analysis of variables affecting mouse protection efficacy of whole organism Brucella vaccines and vaccine candidates. BMC Bioinformatics. 2013, 14(Suppl 6):S3. PMID: 23735014. PMCID: PMC3633026.

100

WARN

VO:0001214

a bacterial vaccine that uses inactivated bacterial organism.

101

WARN

VO:0001215

an anti-reproductive vaccine for cattle. The vaccine is based on the established principle that antibodies to the hypothalamic releasing hormone, gonadotrophin releasing hormone (GnRH) block the action of GnRH on pituitary secretion of luteinizing hormone and follicle stimulating hormone, leading to gonadal atrophy in mammals. The vaccine comprises an immunogenic GnRH:ovalbumin conjugate formulated in a novel double adjuvant system and is administered in a two-dose treatment regimen.

102

WARN

VO:0001395

a vaccine that contains two or more individual vaccines.

103

WARN

VO:0002115

A horse Encephalomyelitis-Influenza-West Nile Virus vaccine that is inactivated and manufactured by Wyeth Pharmaceuticals Inc.

104

WARN

VO:0002483

A horse vaccine that protects against EEE, VEE, WEE, influenza virius infection, and West Nile virus infection.

105

WARN

VO:0003016

A route of administration that located in the stomach, so that the material is taken into body through stomach directly.

106

WARN

VO:0003023

A vaccine prepration process that mixes vaccine lyophilized powder and diluent liquid. The process forms a vaccine that can be used for administration. This term can also be considered as a child term of OBI term 'material combination'.

107

WARN

VO:0003024

a vaccine powder that is freeze-dried and lyophilized.

108

WARN

VO:0003033

a protein vaccine stablizer that is specifically bovine serum albumin.

109

WARN

VO:0003035

a vaccine stabilizer that is generated based on amino acids.

110

WARN

VO:0003036

a vaccine stabilizer that is specifically made by a sucrose.

111

WARN

VO:0003041

an antibiotics vaccine residual that has the antibiotics of neomycin.

112

WARN

VO:0003042

the vaccine antiegn that induces protective immune response.

113

WARN

VO:0003048

when the vaccination of a significant portion of a population (or herd), in contagious diseases that are transmitted from individual to individual, chains of infection are likely to be disrupted, so the large numbers of a population are immue or less susceptible to the disease.

114

WARN

VO:0003050

A role inheres in a material eneitity that union itself chemically with a relative weak vaccine antigen to form a new whole that can create an effective miinuogen. The

115

WARN

VO:0003057

an vaccine-induced host response that shows augmented protection and cellular immunity after a host protein is used as adjuvant.

116

WARN

VO:0003247

The site that is the part of the host body and the entrance point where a vaccine is administered.

117

WARN

VO:0003336

a vaccine-induced down-regulation gene expression that occurs in live attenuated vaccine and compared with the host system infected with live wild type virulent strain which is the parent strain of this live attenuated vaccine.

118

WARN

VO:0003348

A vaccine-induced up-regulation gene expression that occurs in live attenuated vaccine and compared with the host system infected with live wild type virulent strain which is the parent strain of this live attenuated vaccine.

119

WARN

VO:0004400

An autologous dendritic cell vaccine with potential immunostimulatory activity. Dendritic cells harvested from a prostate cancer patient are transfected with the mRNA encoding for prostate specific antigen (PSA), a tumor marker secreted by prostatic epithelial and ductal cells. When reintroduced back to the patient, these PSA RNA pulsed autologous dendritic cells may elicit a cytotoxic T-cell (CTL) response against PSA-positive prostate cancer cells.

120

WARN

VO:0006094

IAO:0000116

Chemical Nature: Nucleic acid Mechanism of Action: TLR9 agonist Immune profile induced: Mixed Th1/Th2 Route of immunization: IM, SQ Point of Contact: Nikolai Petrovsky, Vaxine LTD

121

WARN

VO:0006105

A vaccine adjuvant which is a small molecule adjuvant that is able to induce a mixed Th1/Th2 response and active innate immunity.

122

WARN

VO:0007336

A cancer vaccine that consists of of irradiated autologous tumor cells admixed with GM-CSF-secreting bystander cells. The CD8+ T cells can react against CLL-associated antigens. Autologous tumor cell vaccination is an effective strategy to advance long-term leukemia control following allogeneic hematopoietic stem cell transplantation (allo-HSCT).

123

WARN

VO:0007342

A cancer vaccine that is composed of oxidized ovarian tumor cell lysate, with potential immunostimulatory and antineoplastic activities. The autologous oxidized ovarian tumor cell lysate vaccine exposes the immune system to an undefined amount of tumor-associated antigens (TAAs), which may result in the induction of both anti-tumor cytotoxic T-lymphocytes (CTLs) and antibody-dependent responses against TAA-expressing cells, leading to tumor cell lysis. Compared to non-oxidized tumor cell lysate vaccines, oxidized tumor cell lysate vaccines induce necrotic cell death, increase the immunogenicity of the TAAs and may enhance the anti-tumor immune response. Cyclophosphamide/Fludarabine Lymphodepletion and an immunomodulatory combination of Interferon-alpha Bevacizumab and Aspirin followed by adoptive transfer of vaccine-primed ex vivo CD3/CD28-costimulated peripheral blood autologous T cells and vaccination with whole tumor vaccine administered intradermally in combination with Bevacizumab in patients with recurrent ovarian cancer fallopian tube or primary peritoneal cancer may help treat their tumors. Patients will receive 5-10 million cells intradermally.

124

WARN

VO:0007348

A cancer vaccine made up of Bcl-xl_42 and the adjuvant CAF09b for patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases. B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous diseases, Bcl-xl_42 is a peptide fragment of the full protein and can lead to the death of cancer cells. CAF09b improves the activation of the immune system.

125

WARN

VO:0007354

A vaccine comprised of autologous dendritic cells pulsed with mRNA-encoded Carcinoembryonic Antigen (CEA) targeting tumor cells expressing CEA.

126

WARN

VO:0007364

A cancer vaccine consisting of the bcr-abl b2a2 fusion oncoprotein, frequently expressed in chronic myelogenous leukemia (CML), with potential antineoplastic activity. Vaccination with the bcr-abl (b2a2)-derived peptide vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells that express the bcr-abl b2a2 fusion protein. The vaccine is made from made from the proteins that cause leukemia cells in CML to behave abnormally. Imatinib mesylate is the standard therapy for CML and blocks the function of this protein. In combination, these may decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.

127

WARN

VO:0007380

4582

128

WARN

VO:0007395

4582

129

WARN

VO:0007410

A cell-based cancer vaccine consisting of autologous dendritic cells (DCs) pulsed with mesothelioma tumor lysate with potential immunostimulating and antineoplastic activities. Upon administration, mesothelioma tumor lysate-pulsed autologous dendritic cell vaccine may stimulate the host immune system to mount a specific cytotoxic T lymphocyte (CTL) response against mesothelioma tumor cells, resulting in tumor cell lysis.

130

WARN

VO:0007475

4582

131

WARN

VO:0007477

An autologous dendritic cell (DC) cancer vaccine with GITRL RNA-transfected that has potential immunostimulatory activity.

132

WARN

VO:0007497

A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and survivin in addition to patient-specific melanoma-derived mRNA with potential immunostimulatory and antineoplastic activities. Upon administration, hTERT/survivin/melanoma tumor cell-derived mRNA-transfected dendritic cell vaccine may elicit a highly specific cytotoxic T-cell (CTL) response against melanoma cells expressing hTERT, survivin, and patient-specific melanoma-associated antigens. hTERT, the catalytic subunit of human telomerase, and survivin, a member of the inhibitor of apoptosis (IAP) family of proteins, may be upregulated in certain tumor cell types, playing key roles in tumor cell growth and survival.

133

WARN

VO:0007511

A cancer vaccine prepared as tumor cells are isolated from the lesion site of patients with recurrent or metastatic bladder cancer, and dendritic cells or macrophages are isolated from peripheral blood. The vaccine activates an immune response and the microenvironment of bladder cancer lesions, and improves the anti-recurrence treatment effect of bladder cancer.

134

WARN

VO:0007513

A cancer vaccine for patients with Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer to receive ex vivo-generated tumor antigen-loaded dendritic cells (DCs), which can prime lymphocytes and regulate and maintain immune responses. The vaccine may boost T cell immunity targeted against breast cancer, enhance chemotherapy effectiveness and decrease tumor metastagenicity, and decrease the recurrence rates of LA TNBC and ER+/HER2- BC.

135

WARN

VO:0007526

A cancer vaccine comprised of estrogen receptor alpha (ERa; estrogen receptor 1; ESR1) mutant peptides, combined with the immunoadjuvants granulocyte-macrophage colony-stimulating factor (GM-CSF) and montanide ISA, with potential immunomodulating and antineoplastic activities. ESR1 mutant peptides in the ESR1 peptides/GM-CSF/montanide ISA vaccine may activate the immune system to induce an immune response against tumor cells expressing these ESR1 mutations. Cancer peptides used in this vaccine are derived from the estrogen receptor and are combined with the adjuvant Montanide ISA and GM-CSF to enhance their immune response. The vaccine may improve outcomes of patients with endocrine resistant breast cancer.

136

WARN

VO:0007532

A cancer vaccine containing dendritic cells (DCs) that are transfected with messenger RNA (mRNA) encoding human telomerase reverse transcriptase (hTERT) and LAMP.

137

WARN

VO:0007537

A conjugate consisting of fluorescein isothiocyanate (FITC) conjugated with folate with potential antineoplastic activity. Folate-FITC binds to folate receptors, which are overexpressed on the surfaces of many cancer cells including kidney and ovarian cancer cells. Once bound to the cancer cell through the folate moiety of the conjugate, circulating anti-fluorescein antibodies may recognize and bind to the FITC moiety, resulting in antibody-dependent cellular cytotoxicity.

138

WARN

VO:0007557

4582

139

WARN

VO:0007567

253970502

140

WARN

VO:0007664

A cancer vaccine comprised of K562 cells transfected with the granulocyte macrophage-colony stimulating factor (GM-CSF) gene with potential immunopotentiating properties. This vaccine may stimulate the host immune system to produce an antitumoral T-lymphocyte response, thereby inhibiting tumor growth. A cultured cell line is genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from a patient. Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia. The vaccine can also be combined with stem cell transplantation. The vaccine may induce an immune response to common myeloid antigens (e.g., Wilms' tumor-1 [WT-1], survivin, or proteinase-3) in patients with Myelodysplastic Syndrome.

141

WARN

VO:0007665

NCT: https://clinicaltrials.gov/study/NCT00840931

142

WARN

VO:0007667

A cancer vaccine that uses irradiated, adenovirus transduced autologous myeloblasts to secrete granulocyte-macrophage colony-stimulating factor (GVAX) early after allogeneic hematopoietic stem cell transplantation (HSCT) to induce potent immune responses. The vaccine may prevent advanced myelodysplastic syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), or acute myeloid leukemia (AML) from relapsing after stem cell transplant. The patients own cancer cells are engineered to produce a protein called GM-CSF, which can be effective in stimulating a powerful immune response specific to that cancer.

143

WARN

VO:0007672

A cancer vaccine made from a person's white blood cells mixed with tumor proteins (HLA-A1- and HLA-A2.1-restricted peptides derived from melanoma-associated tumor antigens) and CD40-ligand, and may make the body build an immune response to kill tumor cells. This is combined with denileukin diftitox, which

144

WARN

VO:0007678

A cancer vaccine derived from the immunomodulatory enzyme indoleamine 2,3-dioxygenase (IDO) with potential immunomodulating and antineoplastic activities. It may activate the immune system to induce an immune response against IDO-expressing tumor cells, which may restore the proliferation and activation of various immune cells including cytotoxic T-lymphocytes (CTLs), natural killer cells (NKs), and dendritic cells (DCs), and may eradicate IDO-expressing tumor cells through a CTL-mediated response. This vaccine, using a small fragment of IDO, can be used in combination with either Ipilimumab or Vemurafenib to treat maligt melanoma that has metastasized.

145

WARN

VO:0007693

A cancer vaccine containing a mixture of killed bacteria with potential immunostimulatory and antineoplastic activities. Mixed bacteria vaccine (MBV or Coley's toxins) consists of a pyrogenic bacterial lysate derived from Serratia marcescens and Streptococcus pyogenes; the active components in the lysate may be lipopolysaccharide (LPS), a component of the Gram-negative bacterial cell wall of Serratia, and streptokinase, an enzyme produced by Streptococcus pyogenes. LPS has been shown to stimulate the host humoral immune response and induce the release of various antitumor cytokines such as tumor necrosis factor (TNF) and interleukin-12 (IL-12). The mixed bacteria vaccine (MBV) is administered at a starting dose of 250 EU (1 µL) and escalated in each patient to a dose inducing the desired pyrogenic effect, defined as a body temperature of 38°C to 39.5°C. It is given to patients with maligt tumors that expressed the NY-ESO-1 antigen. It is designed to induce immunological effects and tumor response following vaccination.

146

WARN

VO:0007695

A cancer vaccine made with dendritic cells (DCs) pulsed with mRNA encoded tumor antigens. These personalized cell vaccines may lead to antitumor specific T cell responses.

147

WARN

VO:0007702

A cancer vaccine adjuvant and synthetic Toll-like receptor (TLR) type 1 and 2 ligand composed of a lipopeptide containing a water-soluble derivative of Pam3-Cys, the biologically active component of the mycobacterial 19 kDa lipoprotein of mycobacteria, that is covalently linked to a synthetic peptide (GDPKHPKSF), with potential immunostimulating activity. TLR1/2 agonist Pam3Cys-GDPKHPKSF targets, binds to and activates TLR1/2, which induces CD8- and T-helper 1 CD4-positive T-cell responses. This may enhance T-cell-mediated immune responses when administered together with peptide vaccine. A multi-peptide vaccine can be used in combination with the TLR1/2 ligand XS15 in CLL patients undergoing ibrutinib-based regimes. Applying several CLL-associated antigens simultaneously increases the likelihood that a multi-clonal, broad and at the same time highly specific T-cell response is mounted, thereby preventing potential tumor escape mechanisms. The novel TLR1/2 ligand (XS15, developed in Tübingen) that (i) is water-soluble and (ii) GMP-amenable, (iii) non-toxic and (iv) effective in inducing T cells specific for peptides in vivo. A personalized multi-peptide vaccination can also be used in combination with the TLR1/2 ligand XS15 for individual patients with advanced solid and hematological maligcies without any approved treatment options.

148

WARN

A cancer vaccine consisting of autologous DCs loaded with immunogenic peptides derived from autologous cancer cells, with potential immunomodulating and antineoplastic activities. Vaccination with the neoantigen-loaded autologous DC vaccine stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing the neoantigens, which results in tumor cell lysis. Neoantigens arising from the mutations of the tumor genome expressed specifically on the tumor cell instead of normal cells, suggesting that vaccines targeting neoantigens should generate a highly tumor-specific response with minimal off-target effects. Neoantigens are identified from tumor tissues from a gastric cancer, hepatocellular carcinoma, lung cancer or colorectal cancer patient. Dendritic cells are then primed with synthesized peptides. The vaccine can be combined with microwave ablation ti treat patients with Hepatocellular Carcinoma (HCC). It can also be combined with Anti-PD1 (Nivolumab) as for patients with resected Hepatocellular Carcinoma (HCC) and Liver Metastases From Colorectal Cancer (CRLM).

149

WARN

NCT: https://clinicaltrials.gov/study/NCT03871205

150

WARN

NCT: https://clinicaltrials.gov/study/NCT04147078

151

WARN

NCT: https://clinicaltrials.gov/study/NCT04912765]

152

WARN

VO:0007713

A cancer vaccine comprised of synthetic peptides derived from the cancer-testis antigen NY-ESO-1, preferentially expressed antigen in melanoma (PRAME), human melanoma antigen A3 (MAGE-A3) and the human Wilms tumor protein-1 (WT-1), with potential immunostimulating and antineoplastic activities. NY-ESO-1/PRAME/MAGE-A3/WT-1 peptide vaccine may stimulate the immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing NY-ESO-1, PRAME, MAGE-A3 and WT-1, resulting in tumor cell lysis. As proteins are degraded in cells, peptides are presented on the surface of these cells as a complex with tissue type molecules (HLA molecules). T-cells may then recognize the peptide-HLA complexes, via its T-cell receptor, potentially resulting in tumor-cell killing, if sufficient priming takes place. Cancer testis antigens (CTA's) are known to be immunogenic and are only expressed at immunoprivileged sites, thus out of reach of immune responses, and on cancer cells, making them ideal targets for therapeutic cancer vaccination. The CTA's chosen were NY-ESO-1, MAGE-A3 and PRAME. WT-1 is additionally included as this protein has proven to be an important antigen in hematological maligcies. It is combined with azacitidine for treatment of patients with high-risk myelodysplastic syndrome or acute myeloid leukemia.

153

WARN

VO:0007715

A cancer vaccine composed of autologous ovarian cancer antigens obtained from hydrolyzed, inactivated blood and tumor tissue of patients with ovarian cancer, with potential immunostimulatory and antineoplastic activities. The ovarian cancer antigens stimulate the immune system and activate a cytotoxic T-lymphocyte (CTL) immune response against ovarian cancer cells. Ovarian cancer patients can be given one pill a day for three months.

154

WARN

VO:0007718

A cancer vaccine made up of CPC-P501 protein formulated with the adjuvant AS15. Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, can be treated with the P501-AS15 vaccine.

155

WARN

VO:0007725

A cancer vaccine for melanoma. Melanomas have mutations (changes in genetic material) that are specific to an individual patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. These proteins used in a vaccine may induce strong immune responses, which may help the participant's body fight any tumor cells that could cause the melanoma to come back in the future. NeoVax is a long-peptide vaccine targeting up to 20 personal neoantigens per patient for patients with surgically resected stage IIIB/C or IVM1a/b melanoma. There was long-term persistence of neoantigen-specific T cell responses following vaccination, with ex vivo detection of neoantigen-specific T cells exhibiting a memory phenotype, as well as diversification of neoantigen-specific T cell clones over time, with emergence of multiple T cell receptor clonotypes exhibiting distinct functional avidities. There was also tumor infiltration by neoantigen-specific T cell clones after vaccination and epitope spreading, suggesting on-target vaccine-induced tumor cell killing. Personal neoantigen peptide vaccines thus induce T cell responses that persist over years and broaden the spectrum of tumor-specific cytotoxicity in patients with melanoma.

156

WARN

VO:0007726

A cancer vaccine that contains 6 synthetic peptides mixed with the adjuvant Montanide™. The peptides were selected to induce T cell responses against 12 domit epitopes from 7 cancer testis antigens (CTAs), which are the most frequently expressed CTAs in colorectal cancer. The 6 peptides were optimized to induce long lasting CRC specific T cell responses. Colorectal cancer peptide vaccine PolyPEPI1018 potentially elicits a cytotoxic T-lymphocyte response against colorectal tumors expressing the CTAs associated with the vaccine, which may result in a reduction in tumor cell proliferation.

157

WARN

VO:0007727

A cancer vaccine consisting of whole irradiated heterologous melanoma cells which express multiple melanoma-related antigens. Polyvalent melanoma vaccine may stimulate an antitumoral cytotoxic T-cell immune response in the host, resulting in inhibition of tumor cell proliferation and tumor cell death. Vaccines may make the body build an immune response and kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Interferon alfa-2b may interfere with the growth of tumor cells. Treatment with this combination may help treat melanoma.

158

WARN

VO:0007730

A cancer vaccine containing seven 17 amino acids long synthetic RAS oncogene-encoded peptides representing the most common codon 12 and 13 oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS), with potential immunomodulating and antineoplastic activities. The vaccine may stimulate a specific CD4-positive helper T-lymphocyte- and cytotoxic T-lymphocyte (CTL)-mediated immune response against RAS mutant-specific-expressing cancer cells, resulting in an inhibition of tumor cell proliferation and tumor cell death. The vaccine can be given in combination with Balstilimab and QS-21 for patients with pancreatic cancer to increase efficacy.

159

WARN

VO:0007733

A cancer vaccine that consists of the oligosaccharide antigen sialyl Lewis (CA19-9) conjugated to the nonspecific immunomodulator keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. The sialyl Lewis-keyhole limpet hemocyanin conjugate vaccine may induce production of IgG and IgM antibodies as well as trigger an antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing the sialyl Lewis antigen. The vaccine therapy together with QS21 may cause a stronger immune response and kill more tumor cells.

160

WARN

VO:0007735

A cancer vaccine made with GMCSF transgene that directly stimulates increased expression of tumor antigen(s) and enhances dendritic cell migration to the vaccination site. TGFβ2 blockade following intracellular TGFβ2 antisense gene expression reduces production of immune inhibiting activity at the vaccine site. This vaccine integrates enhancement of an anticancer immune response concurrently with a reduction in cancer-induced immune suppression. Autologous cancer cells are harvested from patients with advanced refractory cancer, and a TGFβ2 antisense / GMCSF expression vector plasmid is constructed. The autologous cancer tissue is irradiated and electrocorporated with the vector.

161

WARN

VO:0007740

A cancer vaccine that is composed of dendritic cells pulsed with tumor cells lysates that stimulate a potent and specific cell mediated anti-tumor immune response. It can be used in combination with high-dose chemotherapy and hematopoietic stem cell transplantation (HSCT). The combination may increase overall survival and progression-free survival for patients with high-risk pediatric and young adult tumors (localized solid tumors such as, sarcoma, neuroblastoma, and Wilms' tumor).

162

WARN

VO:0007748

USA licensed vaccine for veterinary uses approved by USDA.

163

WARN

VO:0010252